FDA Closes the Supplement Door on Amanita Muscaria: Federal Exposure for Florida Mushroom Gummy Sellers

If your shop, distribution company or website sells gummies, tinctures or capsules built on Amanita muscaria, the federal government has now told the industry in writing that there is no lawful label for the product. On October 20, 2026, FDA posted a warning letter holding that Amanita muscaria extract and its active compounds are new dietary ingredients with no adequate safety record, so a supplement containing them is adulterated. FDA had already ruled the mushroom out of conventional food in December 2024. Both doors are now closed, and that changes what every seller is presumed to know.

Conventional food is out. Supplements are out. FDA has addressed both labels.

Key Takeaways

• FDA's September 29, 2026 warning letter treats Amanita muscaria, ibotenic acid, muscimol and muscarine as new dietary ingredients under 21 U.S.C. § 350b.
• A supplement containing them is adulterated under 21 U.S.C. § 342(f)(1)(B), and shipping it interstate is a prohibited act under 21 U.S.C. § 331(a).
• A first FDCA violation is a strict-liability misdemeanor; intent to defraud or mislead makes it a three-year felony under 21 U.S.C. § 333.
• Florida smoke shops, convenience stores and online sellers still stocking amanita gummies now face a documented-notice problem, not a regulatory gray area.
• Audit inventory, supplier records and website copy before an FDA OCI investigation or a Southern District of Florida grand jury subpoena arrives.

What Happened

FDA's Human Foods Program issued the warning letter on September 29, 2026, to a Toronto-based company that takes U.S. orders online for products represented as containing Amanita muscaria. FDA posted it on October 20. The agency's evidence was a review of the company's website in May 2026. The letter describes no inspection, no sample and no undercover purchase. The website was the case.

The legal reasoning is short and decisive. The labels declared Amanita muscaria extract as a dietary ingredient under 21 U.S.C. § 321(ff). FDA then said it has no information that Amanita muscaria, its extract, ibotenic acid, muscarine or muscimol were marketed as dietary ingredients before October 15, 1994. That makes each a new dietary ingredient under 21 U.S.C. § 350b, which requires either prior presence in the food supply or an advance safety notification. Without either, FDA found "inadequate information to provide reasonable assurance" of safety and declared the products adulterated under 21 U.S.C. § 342(f)(1)(B). Introducing them into interstate commerce violates 21 U.S.C. § 331(a). The company received 15 working days to respond and a warning of "seizure and injunction."

"Inadequate information to provide reasonable assurance"— FDA warning letter on Amanita muscaria products, September 29, 2026

The letter follows FDA's December 18, 2024 notice that Amanita muscaria and the same three constituents are unapproved food additives that do not meet the GRAS standard and are not authorized in conventional food. At that time FDA said it was "also evaluating" their use in dietary supplements. That evaluation is now a published enforcement position.

What the Government Is Building

Read the two documents together and the enforcement theory is plain. Conventional food is out because the ingredients are unapproved food additives. Supplements are out because they are new dietary ingredients with no safety showing. A seller who relabels a gummy from "edible" to "dietary supplement" has not found a path. FDA has addressed both labels.

The method matters as much as the holding. FDA built this letter from a website: product pages, dosing language, calming and mood claims, and the checkout page. The agency's internet-pharmacy letters this fall rested on the same kind of dated website review. For a Florida seller, the government's first exhibit is already public and already archived.

FDA built this letter from a website: product pages, dosing language, calming and mood claims, and the checkout page. The government's first exhibit is already public and already archived.

It also fits a pattern on the wellness shelf. On October 14, 2026, DEA published a notice of intent to temporarily place 7-OH above a specified threshold in Schedule I. Kratom derivatives, amanita gummies and hemp-adjacent products sit side by side in smoke shops and convenience stores from Miami to Palm Beach County, and federal agencies are working that shelf one product at a time.

Exposure and Charges Under the FDCA and Related Statutes

21 U.S.C. § 333(a)(1) makes any violation of § 331 a misdemeanor punishable by up to one year. In United States v. Park, 421 U.S. 658 (1975), the Supreme Court held that a corporate officer with authority to prevent or correct a violation can be convicted without proof of intent. Owners and managers of distribution companies are exactly who that doctrine reaches.

Under § 333(a)(2), the same conduct becomes a felony carrying up to three years when committed with intent to defraud or mislead, or after a prior FDCA conviction. This is where notice becomes the case. A warning letter to one company is public. An FDA statement to the whole industry is public. A seller who reads both, keeps the product and changes the label to avoid attention hands a prosecutor the intent evidence the felony requires.

Other charges follow the facts. False health claims sold through a website can support wire fraud under 18 U.S.C. § 1343, which carries up to 20 years. An agreement among importers and distributors to keep product moving past FDA can support conspiracy to defraud the United States under 18 U.S.C. § 371. Importing merchandise contrary to law implicates 18 U.S.C. § 545, a real concern for product sourced from overseas. FDA can also proceed civilly by seizure under 21 U.S.C. § 334 and injunction under 21 U.S.C. § 332 without any criminal case.

The statute reaches anyone who introduces the product into interstate commerce, and § 331(c) separately reaches receipt in interstate commerce and delivery onward. Importers, white-label manufacturers, wholesalers, website operators and multi-location retail chains all sit in that chain.

Critical Mistakes Florida Sellers Make Early

• Treating the letter as someone else's problem. It went to one company, but its legal position applies to every product with the same ingredient.
• Relabeling instead of pulling product. Changing "supplement" to "novelty" or "not for human consumption" while selling the same gummy is the conduct that turns a misdemeanor into felony intent. FDA rejected research-use-only labels on peptide websites this year for the same reason.
• Deleting web pages or supplier emails after reading the news. Destroying records once an investigation is foreseeable invites a charge under 18 U.S.C. § 1519, and obstruction is easier to prove than the underlying offense.
• Talking to FDA investigators or federal agents without counsel. A false or incomplete answer can become its own charge under 18 U.S.C. § 1001.
• Assuming no letter means no case. FDA does not have to warn every seller before it refers a matter for prosecution.

Strategic Defense Approach

Federal investigation defense in an FDCA matter starts with a privileged inventory: what product is on hand, where it came from, what the labels and website say, and when each changed. Counsel can then document a decision to stop sales, quarantine stock and preserve records. That record is the strongest good-faith evidence a seller can create. If you supply other retailers, notify them in writing.

Stop sales, quarantine stock and preserve records. That record is the strongest good-faith evidence a seller can create.

If you have received a grand jury subpoena, an FDA records request or a call from an FDA OCI agent, the first question is your status: witness, subject or target. A federal target letter attorney or fda investigation attorney can usually learn that from the AUSA and shape what happens next. A proffer session attorney protects your statements if cooperation makes sense. Pre-charge negotiation with the AUSA, supported by proof that the company acted on the December 2024 notice or on this letter, matters to a prosecutor choosing between a misdemeanor, a felony or no charge.

If charges are filed, a white collar defense attorney will focus on knowledge and intent, on who in the company had authority under Park, and at sentencing on the gain and loss figures that drive the guidelines.

Why Timing Matters

Every week a product stays on the shelf after October 20, 2026 is a week a prosecutor can describe as knowing conduct. The window to fix the record is now, while the facts still read as a business that acted on new information.

Common Questions

Facing an FDA Investigation Over Amanita or Wellness Products in Florida?

If you have received an FDA records request, a federal grand jury subpoena, or a visit from agents about amanita, kratom or other wellness products, speak with counsel before you respond. AMC Defense Law provides Southern District of Florida federal defense and represents clients in federal investigations in the Middle District of Florida and nationwide. Every consultation is confidential. Request a confidential consultation.

Aaron M. Cohen represents clients in FDA and federal investigations in the Southern and Middle Districts of Florida and nationwide.

If you or your loved ones have been arrested or contacted by federal agents, call Aaron M. Cohen, 24 hours a day to get help.

About the author. Aaron M. Cohen is the founder and principal attorney of AMC Defense Law, a criminal defense firm in Boca Raton, Florida, with more than 30 years of experience in state and federal courts. He is admitted to practice in Florida, New York, New Jersey, and the District of Columbia, and before the United States District Courts for the Southern and Middle Districts of Florida, the Southern, Eastern, and Western Districts of New York, the District of New Jersey, and the Northern District of Texas. He appears pro hac vice in other federal districts nationwide. The firm represents clients in federal investigations and prosecutions involving healthcare fraud, Anti-Kickback Statute matters, DME and telemedicine fraud, peptide and compounded-drug enforcement, controlled-substance and drug conspiracy cases, financial crimes, and complex federal litigation, in Florida and nationwide.

This article is for general informational purposes only and is not legal advice. Reading it does not create an attorney-client relationship. Every case turns on its own facts, and past results do not guarantee a similar outcome. Attorney advertising.